Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
As the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs.
Search
-
-
Medicare Part D: A First Look at Medicare Prescription Drug Plans in 2022
Issue BriefThis issue brief provides an overview of the Medicare Part D prescription drug benefit market for 2022, with a primary focus on stand-alone drug plans. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D drug plans available in 2022.
-
Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending
News ReleaseTwenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis.
-
Will President Trump’s Executive Order Lower Drug Prices?
Quick TakeUltimately, assessing the impact of President Trump’s newest iteration of “Most Favored Nation” drug pricing depends on details that have yet to be fleshed out.
-
What to Know About the Medicare Open Enrollment Period and Medicare Coverage Options
Issue BriefEach year, Medicare beneficiaries have an opportunity to make changes to how they receive their Medicare coverage during the nearly 8-week annual open enrollment period. This brief answers key questions about the Medicare open enrollment period and Medicare coverage options.
-
Eliquis’s New Lower Direct-to-Consumer Price is Still Higher Than Medicare’s Negotiated Price
Quick TakeVoluntary efforts by drug companies to lower prices on selected medications, such as this new discounted price for Eliquis and previous price reductions on certain insulin products, could expand access to lower-priced drugs for some patients, but are not likely to improve prescription drug affordability in the U.S. on a widespread basis.
-
The Trump Administration is Reducing Enhanced Support for the Part D Stand-Alone Drug Plan Market
Quick TakeIn announcing these changes, CMS states that it is “facilitating the Part D program’s return to operating under regular market conditions.” Increasingly, however, these regular conditions appear unfavorable to the ongoing stability of the stand-alone prescription drug plan market, further tilting the playing field towards Medicare Advantage.
-
Tariffs Are Driving 2026 Health Insurance Premiums Up
Quick TakePresident Trump has vowed to impose tariffs on a wide variety of goods from multiple countries. While consumers may expect the price of some imported goods to go up, what may be surprising is that these tariffs are already driving health insurance premiums up.
-
Utilization and Spending Trends in Medicaid Outpatient Prescription Drugs, 2015-2019
Issue BriefPrescription drug spending in Medicaid and other health programs has returned to the national policy debate. This analysis examines Medicaid outpatient prescription drug utilization and spending before rebates over the 2015 to 2019 period, which is helpful for understanding recent cost drivers and areas for targeted policy action.
-
Key Facts About Medicare Part D Enrollment, Premiums, and Cost Sharing in 2025
Issue BriefThe Medicare Part D program provides an outpatient prescription drug benefit to more than 50 million older adults and people with long-term disabilities in Medicare who enroll in private plans, including stand-alone prescription drug plans (PDPs) to supplement traditional Medicare and Medicare Advantage prescription drug plans (MA-PDs) that include drug coverage and other Medicare-covered benefits. This brief analyzes Medicare Part D enrollment and costs in 2025 and trends over time, based on data from the Centers for Medicare & Medicaid Services (CMS).